UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 130

Sortiert nach

204 speaker ROLE OF ADJUVANT CHEMOTHERAPY

Radiotherapy and oncology, 2011, Vol.99, p.S79-S80

Sculier, J.P

2011

Link zum Volltext

Verfügbarkeit prüfen

Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study

Lung cancer (Amsterdam, Netherlands), 2013-11, Vol.82 (2), p.340-345

2013

Link zum Volltext

Verfügbarkeit prüfen

Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis

The European respiratory journal, 2001-10, Vol.18 (4), p.705-719

2001

Link zum Volltext

Verfügbarkeit prüfen

The lung cancer patient at the emergency department: A three-year retrospective study

Lung cancer (Amsterdam, Netherlands), 2013-05, Vol.80 (2), p.203-208

2013

Link zum Volltext

Verfügbarkeit prüfen

Medical anticancer treatment of lung cancer associated with comorbidities: A review

Lung cancer (Amsterdam, Netherlands), 2015-03, Vol.87 (3), p.241-248

2015

Link zum Volltext

Verfügbarkeit prüfen

67O ARE FIRST-LINE PLATINUM-BASED (PT) REGIMENS IMPROVING SURVIVAL IN COMPARISON WITH NON-PLATINUM (NPT) CHEMOTHERAPY (CT) IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)? A META-ANALYSIS (MA) OF RANDOMISED TRIALS

Lung cancer (Amsterdam, Netherlands), 2013-05, Vol.80, p.S31-S31

2013

Link zum Volltext

Verfügbarkeit prüfen

OC-0062: An invidual data metaanalysis of phase II trials of adjuvant or induction chemotherapy for NSCLC treated with chemoRT

Radiotherapy and oncology, 2014, Vol.111, p.S23-S23

2014

Link zum Volltext

Verfügbarkeit prüfen

A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2009-05, Vol.64 (2), p.187-193

2009

Link zum Volltext

Verfügbarkeit prüfen

Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): A phase II randomised study by the European Lung Cancer Working Party

Lung cancer (Amsterdam, Netherlands), 2012-09, Vol.77 (3), p.605-610

2012

Link zum Volltext

Verfügbarkeit prüfen

EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: A positive association

Lung cancer (Amsterdam, Netherlands), 2008-10, Vol.62 (1), p.35-44

2008

Link zum Volltext

Verfügbarkeit prüfen

Valproate―doxorubicin: promising therapy for progressing mesothelioma. A phase II study

The European respiratory journal, 2011-01, Vol.37 (1), p.129-135

2011

Link zum Volltext

Verfügbarkeit prüfen

Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53

The European respiratory journal, 2003-05, Vol.21 (5), p.753-758

2003

Link zum Volltext

Verfügbarkeit prüfen

Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature

Lung cancer (Amsterdam, Netherlands), 2005-07, Vol.49 (1), p.13-23

2005

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2000-07, Vol.29 (1), p.67-73

2000

Link zum Volltext

Verfügbarkeit prüfen

Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis

Lung cancer (Amsterdam, Netherlands), 2002-11, Vol.38 (2), p.111-121

2002

Link zum Volltext

Verfügbarkeit prüfen

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis

Lung cancer (Amsterdam, Netherlands), 2000-10, Vol.30 (1), p.23-36

2000

Link zum Volltext

Verfügbarkeit prüfen

A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer

Annals of oncology, 2008-10, Vol.19 (10), p.1691-1697

2008

Link zum Volltext

Verfügbarkeit prüfen

6524 POSTER Primary tumour standardized uptake value (SUV max) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Staging Project

European journal of cancer supplements, 2007, Vol.5 (4), p.364-365

2007

Link zum Volltext

Verfügbarkeit prüfen

A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer

Annals of oncology, 2007-06, Vol.18 (6), p.1037-1042

2007

Link zum Volltext

Verfügbarkeit prüfen

Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2006-05, Vol.52 (2), p.219-224

2006

Link zum Volltext

Verfügbarkeit prüfen

Is the tolerance to MIP chemotherapy different between English and other European populations?

Journal of clinical oncology, 2005-09, Vol.23 (25), p.6269-6270

2005

Link zum Volltext

Verfügbarkeit prüfen

Answer to comments on “Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature.” by Berghmans T., et al. [Lung Cancer 49 (2005) 13–23]

Lung cancer (Amsterdam, Netherlands), 2006-02, Vol.51 (2), p.263-265

2006

Link zum Volltext

Verfügbarkeit prüfen

A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma

Lung cancer (Amsterdam, Netherlands), 2005-10, Vol.50 (1), p.75-82

2005

Link zum Volltext

Verfügbarkeit prüfen

Citation indexes do not reflect methodological quality in lung cancer randomised trials

Annals of oncology, 2003-05, Vol.14 (5), p.715-721

2003

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors in non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 1994-11, Vol.11, p.S19-S23

1994

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 130

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(118)
Mit Volltextzugriff
(124)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Life Sciences & Biomedicine
(65)
Humans
(64)
Oncology
(54)
Biological And Medical Sciences
(50)
Medical Sciences
(50)
Male
(32)
Female
(31)
Middle Aged
(31)
Aged
(30)
Pneumology
(28)
Adult
(27)
Lung Neoplasms - Drug Therapy
(27)
Respiratory System
(27)
Tumors Of The Respiratory System And Mediastinum
(27)
Chemotherapy
(25)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(22)
Lung Neoplasms - Pathology
(20)
Lung Neoplasms - Mortality
(17)
Carcinoma, Non-Small-Cell Lung - Pathology
(16)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

204 speaker ROLE OF ADJUVANT CHEMOTHERAPY

Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study

Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis

The lung cancer patient at the emergency department: A three-year retrospective study

Medical anticancer treatment of lung cancer associated with comorbidities: A review

67O ARE FIRST-LINE PLATINUM-BASED (PT) REGIMENS IMPROVING SURVIVAL IN COMPARISON WITH NON-PLATINUM (NPT) CHEMOTHERAPY (CT) IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)? A META-ANALYSIS (MA) OF RANDOMISED TRIALS

OC-0062: An invidual data metaanalysis of phase II trials of adjuvant or induction chemotherapy for NSCLC treated with chemoRT

A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer

Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): A phase II randomised study by the European Lung Cancer Working Party

EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: A positive association

Valproate―doxorubicin: promising therapy for progressing mesothelioma. A phase II study

Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53

Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature

A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer

Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis

A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer

A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer

Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer

Is the tolerance to MIP chemotherapy different between English and other European populations?

Answer to comments on “Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature.” by Berghmans T., et al. [Lung Cancer 49 (2005) 13–23]

A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma

Citation indexes do not reflect methodological quality in lung cancer randomised trials

Prognostic factors in non-small cell lung cancer

Suchergebnisse filtern